The acquisition of OrthoGrid Systems by Zimmer Biomet is likely to positively impact ZBH's stock in the short term. The addition of AI-driven surgical guidance systems, including the Hip AI® platform and two FDA-cleared applications, enhances ZBH's product offerings and positions it as a leader in medical technology. This strategic move is expected to improve surgical accuracy and efficiency, which could lead to increased adoption of ZBH's products and services.